SPAGNOLO, PAOLO
 Distribuzione geografica
Continente #
NA - Nord America 5.812
EU - Europa 408
AS - Asia 292
AF - Africa 3
OC - Oceania 3
Totale 6.518
Nazione #
US - Stati Uniti d'America 5.809
CN - Cina 216
IT - Italia 134
FI - Finlandia 102
SE - Svezia 68
VN - Vietnam 50
GB - Regno Unito 49
DE - Germania 23
IN - India 14
PL - Polonia 9
IE - Irlanda 7
NL - Olanda 6
TR - Turchia 6
HK - Hong Kong 4
CA - Canada 3
CH - Svizzera 2
ES - Italia 2
GH - Ghana 2
NZ - Nuova Zelanda 2
UA - Ucraina 2
AT - Austria 1
AU - Australia 1
BE - Belgio 1
ID - Indonesia 1
JP - Giappone 1
PT - Portogallo 1
RU - Federazione Russa 1
SC - Seychelles 1
Totale 6.518
Città #
Fairfield 1.236
Woodbridge 651
Ashburn 565
Ann Arbor 477
Houston 461
Seattle 430
Cambridge 369
Chandler 344
Wilmington 322
San Diego 114
Medford 107
Princeton 106
Beijing 91
Des Moines 70
Helsinki 59
Dong Ket 50
Roxbury 45
Boardman 38
Padova 23
London 17
Nanjing 17
New York 16
Nanchang 12
Guangzhou 11
Ogden 10
Jinan 8
Dublin 7
Kilburn 7
Pune 7
Rome 7
Milan 6
Orange 6
Shenyang 6
Washington 6
Zabrowo 6
Kunming 5
Falls Church 4
Fuzhou 4
Hebei 4
Hong Kong 4
Hounslow 4
Jiaxing 4
Lappeenranta 4
Redwood City 4
Tianjin 4
Brendola 3
Hefei 3
Siracusa 3
Walnut 3
Zhengzhou 3
Accra 2
Albacete 2
Bhopal 2
Bussero 2
Changsha 2
Chiswick 2
Crotone 2
Hyderabad 2
Istanbul 2
Kharkiv 2
Mahbubnagar 2
New Bedfont 2
Pinehaven 2
Porcari 2
Predaia - Campodenno 2
Recco 2
Redmond 2
Schio 2
Turin 2
Venice 2
Acton 1
Andrano 1
Baotou 1
Barletta 1
Borås 1
Brescia 1
Burlington 1
Caprino Veronese 1
Casaglia 1
Cavarzere 1
Chicago 1
Chieti 1
Dongguan 1
Downham Market 1
Edinburgh 1
Falkenstein 1
Galliera Veneta 1
Genzano Di Roma 1
Gurgaon 1
Hackney 1
Haikou 1
Islington 1
Jakarta 1
Jakubowizna 1
Lecce 1
Lonigo 1
Mahé 1
Mesa 1
Miami Beach 1
New Orleans 1
Totale 5.833
Nome #
High-Resolution CT Change over Time in Patients with Idiopathic Pulmonary Fibrosis on Antifibrotic Treatment 139
The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease 123
Immune inflammation and disease progression in idiopathic pulmonary fibrosis 119
Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) 118
Abandoning developmental silos: what can paediatricians and adult interstitial lung disease physicians learn from each other? 112
Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) Syndrome and Carcinoid Tumors With/Without NECH 108
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis 100
Research highlights from the 2018 ERS International Congress: interstitial lung diseases 99
High-Resolution Computed Tomography (HRCT) Reflects Disease Progression in Patients with Idiopathic Pulmonary Fibrosis (IPF): Relationship with Lung Pathology 97
Recent advances in the pathobiology and clinical management of lymphangioleiomyomatosis 91
Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis 90
Immunogenetics of Disease-Causing Inflammation in Sarcoidosis 88
Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy 86
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives 86
IPF in 2016: towards a better diagnosis 85
Update on therapeutic management of idiopathic pulmonary fibrosis 84
Pharmacological management of IPF 82
Interstitial lung disease in children younger than 2 years 82
Pathogenesis of idiopathic pulmonary fibrosis and its clinical implications 82
New guideline on treatment of idiopathic pulmonary fibrosis 82
Diagnosis and Management of Asthma - The Swiss Guidelines 82
Endobronchial ultrasound-guided transbronchial needle aspiration in sarcoidosis: Beyond the diagnostic yield 82
Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF): an overview of current and future therapeutic strategies 82
Diagnostic Likelihood Thresholds that Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis 82
Sarcoidosis: a Critical Review of History and Milestones 81
Matriptase, protease-activated receptor 2, and idiopathic pulmonary fibrosis: Further evidence for signaling pathway redundancy in this difficult-to-treat disease? 80
Imaging aspects of the diagnosis of sarcoidosis 80
Differential diagnosis of usual interstitial pneumonia: When is it truly idiopathic? 78
Novel Treatments for Idiopathic Pulmonary Fibrosis 78
CA 19-9 serum levels in patients with end-stage idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs): Correlation with functional decline 78
Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis 76
The Role of the Lung's Microbiome in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis 76
Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy 75
Accuracy of individual in the monitoring of long term change in pulmonary sarcoidosis as judge by serial HRCT data 74
Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: A pooled analysis 74
Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis 74
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia syndrome 74
Idiopathic pulmonary fibrosis: An update 73
Chickenpox-Related Multiple Pulmonary Granulomas: A Poorly Recognized Entity 73
Connective tissue diseases, multimorbidity and the ageing lung 73
An important step forward, but still a way to go 73
Pharmacological treatment of idiopathic pulmonary fibrosis: An update 72
Pulmonary sarcoidosis 71
Daily home spirometry: A new milestone in the field of pulmonary fibrosis 69
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 69
Critical review of the evolution of extracellular vesicles’ knowledge: From 1946 to today 69
Classification of different patterns of pulmonary adenocarcinomas 68
Recurrent cerebrospinal fluid basophilia in neurosarcoidosis 66
Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis 65
Hemoptysis and progressive dyspnea in a 67-year-old woman with history of renal transplantation 65
Genetics of idiopathic pulmonary fibrosis: From mechanistic pathways to personalised medicine 65
Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy 64
Genetic determinants of pulmonary fibrosis: Evolving concepts 62
Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy 62
Patients with IPF and lung cancer: diagnosis and management 62
Biopsy in idiopathic pulmonary fibrosis: back to the future 61
Characterization of pulmonary function in 10–18 year old patients with Duchenne muscular dystrophy 61
Pharmacological treatment of idiopathic pulmonary fibrosis: An update 60
Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials 59
Clinical Features and Chest Imaging as Predictors of Intensity of Care in Patients with COVID-19 56
Ventilatory support and mechanical properties of the fibrotic lung acting as a “squishy ball” 56
Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: An international case-cohort study 55
The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis 55
Large cell neuroendocrine carcinoma of the lung: chemotherapy regimen depends on how "large" your diagnostic criteria are 54
Clinical differences in sarcoidosis patients with and without lymphoma: a single-center retrospective cohort analysis 54
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities 53
Clinical trial research in focus: why do so many clinical trials fail in IPF? 51
Pirfenidone and mortality in idiopathic pulmonary fibrosis 50
Genetics of sarcoidosis 49
The role of macrophages in interstitial lung diseases 49
The management of patients with idiopathic pulmonary fibrosis 49
Association between leukocyte telomere length (LTL) and functional decline in patients with Idiopathic Pulmonary Fibrosis (IPF) on antifibrotic treatment 49
Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy 47
The Diagnostic Yield of the Multidisciplinary Discussion in Patients With COVID-19 Pneumonia 47
Pulmonary fibrosis secondary to COVID-19: a call to arms? 46
The value of chest radiograph and computed tomography in pulmonary sarcoidosis 45
Hypersensitivity pneumonitis: A comprehensive review 45
Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment 45
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development 42
Shedding light on developmental drugs for idiopathic pulmonary fibrosis 42
Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone 40
Acute exacerbations of interstitial lung disease: Lessons from idiopathic pulmonary fibrosis 39
Is the imaging inconsistent with usual interstitial pneumonia? Think about idiopathic pulmonary fibrosis then! 37
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis 37
Personalized medicine in idiopathic pulmonary fibrosis: Facts and promises 34
Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs) 34
Genome-wide association studies in idiopathic pulmonary fibrosis: Bridging the gap between sequence and consequence 33
Challenges in Cardiac and Pulmonary Sarcoidosis: JACC State-of-the-Art Review 31
Disease Severity and Prognosis of SARS-CoV-2 Infection in Hospitalized Patients Is Not Associated With Viral Load in Nasopharyngeal Swab 30
Massive lung calcifications in a four times renal transplanted patient: the fight against dialysis, hyper and hypoparathyroidism 30
Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities 29
Chest x-ray or CT for COVID-19 pneumonia? Comparative study in a simulated triage setting 28
Hypersensitivity pneumonitis 27
Looking into the future of sarcoidosis: what is next for treatment? 27
Arrhythmias in Cardiac Sarcoidosis Bench to Bedside: A Case-Based Review 27
Pulmonary Sarcoidosis: Diagnosis and Differential Diagnosis. 27
When the Game Changes: Guidance to Adjust Sarcoidosis Management During the Coronavirus Disease 2019 Pandemic 26
Chronic Bronchitis Affects Outcomes in Smokers without Chronic Obstructive Pulmonary Disease (COPD) 25
Brief communication: Chest radiography score in young COVID-19 patients: Does one size fit all? 25
The role of bronchoscopy in the diagnosis and management of patients with sars-cov-2 infection 24
Totale 6.390
Categoria #
all - tutte 28.979
article - articoli 28.409
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.388


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019581 0 0 0 0 0 0 0 0 3 102 259 217
2019/20201.506 158 52 27 182 195 112 146 182 184 127 93 48
2020/20211.211 43 61 59 60 24 24 239 71 184 234 105 107
2021/20221.517 62 126 235 75 120 75 61 193 146 43 95 286
2022/2023810 184 18 22 86 163 97 1 52 139 6 34 8
2023/2024477 18 86 70 50 51 77 53 45 27 0 0 0
Totale 6.728